Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sarcoma 14Ovarian Neoplasms 6Neoplasms 5Liposarcoma 5Leiomyosarcoma 5Liposarcoma, Myxoid 3Breast Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Osteosarcoma 2Neoplasms by Site 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Ichthyosis, X-Linked 2Endometrial Neoplasms 2Uterine Neoplasms 1Solitary Fibrous Tumors 1Soft Tissue Neoplasms 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Recurrent High Grade Meningioma 1Pancreatic Neoplasms 1Ovarian Diseases 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Malignant mesenchymal tumor 1

Interventions

baricitinib 1VP-102 1Trabectedin 1Spironolactone 1Leuprolide 1Cetuximab 1Cantharidin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Skin Diseases × Trabectedin × Clear all
NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡